Survival rates are lower for patients with high-risk melanoma with mutations
the ONA take:
Researchers from UNC Lineberger Comprehensive Cancer Center analyzed melanoma samples to determine if tumors with the BRAF or NRAS gene mutations indicated poorer prognosis for those patients.
This study was conducted before new treatments for melanoma were approved, including the first BRAF inhibitor approved in 2011. Therefore, the connection between the mutations and outcomes were determined without the influence of the new drugs.
In this study, 912 patients with melanoma were followed for 7 years. All the patients were enrolled through the GEM study, and their diagnoses were made in 2000.
Thirteen percent of patients had tumors with NRAS mutations, 30% had BRAF mutations, and 57% had neither mutation. The researchers found that 73% of patients with high-risk, NRAS-mutated tumors and 71% of patients with high-risk, BRAF-mutated tumors survived 5 years, compared with 82% of high-risk tumors with neither mutation.
Overall, no statistical difference was seen in 5-year survival for people with NRAS or BRAF mutations compared with those people who had no mutation.
However, 5-year survival was lower in people with high-risk tumors with mutations.
No statistical difference was seen in 5-year survival for melanoma patients with NRAS or BRAF mutations.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|